Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Analysis of FOXO3 human targets in Huntington's disease neural stem cells: FOXO3 nuclear induction [RNA-Seq]

ABSTRACT: We report the identification of F0X03 targets in human Huntington's disease neural stem cells. To this end, we generated RNA-seq data upon FOXO3 nuclear induction in human Huntington's disease (HD) and CAG-corrected (C116) neural stem cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE109872 | GEO | 2021/01/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Analysis of FOXO3 human targets in Huntington's disease neural stem cells: FOXO3 nuclear induction [ChIP-Seq]

Project description:We report the identification of F0X03 targets in human Huntington's disease neural stem cells. To this end, we generated FOXO3 ChIP-seq data upon FOXO3 nuclear induction in human Huntington's disease (HD) and CAG-corrected (C116) neural stem cells.

2021-01-30 | GSE109871 | GEO

Analysis of FOXO3 human targets in Huntington's disease neural stem cells: FOXO3 knock-down [RNA-seq2]

Project description:We report the identification of human genes that are differentially expressed upon growth factor deprivation of Huntington's disease neural stem cells, in a FOXO3-knockdown-dependent manner. To this end, we generated RNA-seq data in human Huntington's disease (HD) and CAG-corrected (C116) neural stem cells.

2021-01-30 | GSE126869 | GEO

GENETIC CORRECTION OF HUNTINGTON'S DISEASE PHENOTYPES IN INDUCED PLURIPOTENT STEM CELLS

Project description:Huntington's Disease (HD) is caused by a CAG expansion in the huntingtin gene. Expansion of the polyglutamine tract in the huntingtin protein results in massive cell death in the striatum of HD patients. We report that human induced pluripotent stem cells (iPSCs) derived from HD patient fibroblasts can be corrected by replacing the expanded CAG repeat with a normal repeat using homologous recombination, and that the correction persists in iPSC differentiation into DARPP-32 positive neurons in vitro and vivo. Further, correction of the HD-iPSCs normalized pathogenic HD signaling pathways (cadherin, TGF-?, BNDF, caspase activation), and reversed disease phenotypes such as susceptibility to cell death and altered mitochondrial bioenergetics in neural stem cells. The ability to make patient-specific, genetically corrected iPSCs from HD patients will provide relevant disease models in identical genetic backgrounds and is a critical step for the eventual use of these cells in cell replacement therapy. 16 experimental samples were used overall. There were 8 replicates per group, with one group being the control, and the other being the experimental. Comparison was carried out on the Nimblegen platform.

2012-06-14 | E-GEOD-37547 | biostudies-arrayexpress

GENETIC CORRECTION OF HUNTINGTON'S DISEASE PHENOTYPES IN INDUCED PLURIPOTENT STEM CELLS

Project description:Huntington's Disease (HD) is caused by a CAG expansion in the huntingtin gene. Expansion of the polyglutamine tract in the huntingtin protein results in massive cell death in the striatum of HD patients. We report that human induced pluripotent stem cells (iPSCs) derived from HD patient fibroblasts can be corrected by replacing the expanded CAG repeat with a normal repeat using homologous recombination, and that the correction persists in iPSC differentiation into DARPP-32 positive neurons in vitro and vivo. Further, correction of the HD-iPSCs normalized pathogenic HD signaling pathways (cadherin, TGF-β, BNDF, caspase activation), and reversed disease phenotypes such as susceptibility to cell death and altered mitochondrial bioenergetics in neural stem cells. The ability to make patient-specific, genetically corrected iPSCs from HD patients will provide relevant disease models in identical genetic backgrounds and is a critical step for the eventual use of these cells in cell replacement therapy.

2012-06-15 | GSE37547 | GEO

Analysis of FOXO3 human targets in Huntington's disease neural stem cells

Project description:Analysis of FOXO3 human targets in Huntington's disease neural stem cells

| PRJNA432220 | ENA

Analysis of FOXO3 human targets in Huntington's disease neural stem cells: FOXO3 nuclear induction [ChIP-Seq]

Project description:Analysis of FOXO3 human targets in Huntington's disease neural stem cells: FOXO3 nuclear induction [ChIP-Seq]

| PRJNA432225 | ENA

Analysis of FOXO3 human targets in Huntington's disease neural stem cells: FOXO3 nuclear induction [RNA-Seq]

Project description:Analysis of FOXO3 human targets in Huntington's disease neural stem cells: FOXO3 nuclear induction [RNA-Seq]

| PRJNA432226 | ENA

Analysis of FOXO3 human targets in Huntington's disease neural stem cells: FOXO3 knock-down [RNA-seq2]

Project description:Analysis of FOXO3 human targets in Huntington's disease neural stem cells: FOXO3 knock-down [RNA-seq2]

| PRJNA523628 | ENA

RNA-sequencing of brain microvascular endothelial cell dysfunction in an isogenic juvenile iPSC model of Huntington’s disease

Project description:Huntington's disease (HD) is associated with dysfunction of the blood-brain barrier, including brain microvasscular endothelial cells (BMECs). We report changes in gene expression of induced pluripotent stem cells (iPSCs) and iPSC-derived brain microvascular endothelial cell-like cells (iBMECs) derived from an isogenic pair of iPSCs with either 180 (HD-corrected) or 18 (HD180) CAG repeats in the HTT gene.

2022-02-01 | GSE194416 | GEO

Proteomic analysis of mitochondria from Huntington's Disease patient iPSC-derived neurons

Project description:Huntington's disease is caused by an expanded CAG repeat in the huntingtin gene, yeilding a Huntingtin protein with an expanded polyglutamine tract. Patient-derived induced pluripotent stem cells (iPSCs) can help understand disease; however, defining pathological biomarkers in challanging. Here we used LC-MS/MS to determine differences in mitochondrial proteome between iPSC-derived neurons from healthy donors and Huntington's disease patients.

2023-02-10 | PXD037526 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data